Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (177)	4/22/1998 2:33:00 AM
From: marc ultra	Respond to of 641

Can somebody please clarify something for me .Tamoxifen prevention trials were done specifically on women considered high risk for breast cancer, i.e. a risk equivalent to at least a 60 year old without additional risk factors. These gigantic numbers being thrown around for Evista breast cancer prevention should I assume these were done on women with only a moderate risk of breast Ca? Though I guess since it is being used for post menopausal osteoporosis treatment or prevention that we are likely talking about women in their late forties and up at least. This is an important issue since the higher the risk of the population, the more likely higher efficacy will be seen. Evista increases bone mass somewhat less than estrogen replacement therapy, improves lipids modestly which if proves ok to take in the long run may prevent more deaths from cardiovascular disease than cancer and doesn't cause endometrial cancer so no progesterone needed which is a big deal. When awoman reaches menopause and deciding whether to consider hormones or not the combined factors of mild help preventing osteoporosis, decresed cardiovascular risk and the reduced mental fear of breast cancer which while certainly real has been blown way out of proportion could make Evista an extremely attractive blockbuster drug. The two issues Im concerned about are again how much will it reduce breast cancer in the population actually taking it and also possible competition from similar drugs though since Evista is getting there first it should prevail if no problems.